
ALPHARETTA, Ga., Jan 10, 2012 (BUSINESS WIRE) –
SANUWAVE Health, Inc.
/quotes/zigman/576958 SNWV
+4.76%
, an rising medical
record association focused on a expansion and commercialization of
noninvasive, biological response activating inclination in regenerative
medicine, currently reported announcement of peer-reviewed, preclinical data
conducted during Cleveland Clinic that denote a ability of the
Company’s Pulsed Acoustic Cellular Expression (PACE(R))
record to almost diminution a unpropitious effects of
microcirculatory repairs for certain ischemic (lack of blood flow) and
reperfusion (restoration of blood flow) injuries.
The authors, including Maria Siemionow, MD, PhD, DSc, demonstrated that
a singular diagnosis with PACE technology, delivered possibly before or
after hankie injury, topsy-turvy a disastrous effects of a repairs and
wild liberation of microcirculatory hemodynamics (blood circulation
forces) to healthy levels. The publication, patrician “Pulsed Acoustic
Cellular Expression as a Protective Therapy Against I/R Injury in a
Cremaster Muscle Flap Model,” has been e-published forward of press in Microvascular
Research.
Visit
http://www.sciencedirect.com/science/article/pii/S0026286211002251
to perspective an online epitome of a publication.
Summary of Key Study Findings
–
When tissues were treated with PACE before to injury, an boost in
red blood dungeon quickness in a arterioles adult to 40% was shown compared
to ischemic control (p
–
When PACE was practical after hankie injury, a apportion of functional
capillaries increasing 21% (p
–
When PACE was practical after hankie injury, gene countenance of vascular
endothelial expansion cause (VEGF), a protein that stimulates
angiogenesis (formation of new blood vessels), increasing adult to 180%
compared to ischemic controls.
–
Pre- and post-ischemic PACE diagnosis suppressed countenance of
countless proinflammatory proteins, that has been regularly shown to
definitely change a recovering process.
To a best of a authors’ knowledge, this investigate is a initial to assess
a effects of PACE diagnosis on ischemia and reperfusion repairs during
approach in vivo (in a vital organism) monitoring of a microcirculatory
hemodynamics. In a study, PACE was practical to a skinny square of rat
flesh (cremaster flap) possibly before or after ischemic hankie injury.
Non-ischemic tissue, and ischemic hankie not treated with PACE, served
as controls.
The authors have formerly reported in The Journal of Trauma on
a profitable effects of PACE diagnosis for flesh angiogenesis in an
ischemic rodent initial model. In that study, a authors concluded
that PACE diagnosis correlated with new blood vessel formation, which
they settled might clear a use of PACE as a conditioning diagnosis when
encouragement of hankie neovascularization is compulsory after surgical
trauma. In a benefaction study, Dr. Siemionow and her Cleveland Clinic
colleagues reiterated that PACE diagnosis has many medical applications
due to a reliable ability to urge blood supply to a tissues and
a intensity to kindle angiogenesis and neovascularization,
including intensity focus in clinical cases where hankie ischemia
and reperfusion repairs is approaching or diagnosed.
Christopher M. Cashman, President and CEO of SANUWAVE, said, “This
exciting, assenting preclinical investigate reemphasizes a potential
of a exclusive PACE record as a regenerative height to prevent
and even retreat a damaging effects of marred blood upsurge to tissues.
This study’s commentary have extended clinical implications, such as
intensity applications in reconstructive internal and giveaway flaps, ischemic
wound healing, bake diagnosis and more. Ischemia can start throughout
a body, including in a skin, bone, tendons and ligaments, and organs
such as a heart, mind and kidneys. Left untreated in many of these
tissues, a repairs can be critical and bluster life and limb.”
Mr. Cashman concluded, “PACE diagnosis has a graphic clinical
advantages of being noninvasive, safe, cost-effective and abandoned of
critical side effects compared to other revascularization techniques used
to strengthen or redeem tissues that have suffered ischemia or reperfusion
injury. There is no doubt that a commentary of this investigate build upon
an already vast physique of justification that demonstrates a profitable and
clinically applicable proangiogenic and proinflammatory effects of PACE
technology.”
About dermaPACE(R)
dermaPACE, a Company’s Pulsed Acoustic Cellular Expression (PACE)
record for use in strident and ongoing wound healing, delivers
high-energy acoustic vigour waves in a startle call spectrum to
furnish compressive and tensile stresses on cells and hankie structures
that is designed to foster angiogenic and certain inflammatory
responses, and fast trigger a recovering cascade. This is suspicion to
outcome in microcirculatory improvement, including increasing perfusion
and blood vessel widening (arteriogenesis), a prolongation of angiogenic
expansion factors, extended new blood vessel arrangement (angiogenesis) and
a successive metamorphosis of hankie such as skin, musculoskeletal and
vascular structures. PACE procedures trigger a arising of an
accelerated inflammatory response that speeds wounds into proliferation
phases of recovering and subsequently earnings a ongoing condition to an
strident condition to assistance reinitiate a body’s possess recovering response.
dermaPACE is an Investigational Device in a United States and is
singular by Federal law to investigational use only.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (
www.sanuwave.com )
is an rising regenerative medicine association focused on a development
and commercialization of noninvasive, biological response activating
inclination for a correct and metamorphosis of tissue, musculoskeletal and
vascular structures. SANUWAVE’s portfolio of products and product
possibilities activate biologic signaling and angiogenic responses,
including new vascularization and microcirculatory improvement, helping
to revive a body’s normal recovering processes and regeneration.
SANUWAVE intends to request a PACE record in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead
product claimant for a tellurian wound caring market, dermaPACE, is CE
noted for diagnosis of a skin and subcutaneous soothing hankie and
recently finished a pivotal Phase III, Investigational Device
Exemption (IDE) clinical hearing in a U.S. for a diagnosis of diabetic
feet ulcers. SANUWAVE researches, designs, manufactures, markets and
services a products worldwide, and believes it has demonstrated that
a record is protected and effective in sensitive recovering in chronic
conditions of a feet (plantar fasciitis) and a bend (lateral
epicondylitis) by a U.S. Class III PMA authorized Ossatron(R)
device, as good as sensitive bone and ongoing tendonitis regeneration
in a musculoskeletal sourroundings by a function of its
Ossatron, Evotron(TM) and orthoPACE(R) inclination in Europe.
Forward-Looking Statements
This press recover might enclose “forward-looking statements” within
a definition of a Private Securities Litigation Reform Act of 1995,
such as statements relating to financial formula and skeleton for future
business expansion activities, and are so prospective.
Forward-looking statements embody all statements that are not
statements of chronological fact per intent, faith or current
expectations of a Company, a directors or a officers. Investors
are cautioned that any such forward-looking statements are not
guarantees of destiny opening and engage risks and uncertainties,
many of that are over a Company’s ability to control. Actual
formula might differ materially from those projected in the
forward-looking statements. Among a pivotal risks, assumptions and factors
that might impact handling results, opening and financial condition
are risks compared with a selling of a Company’s product
possibilities and products, unproven pre-clinical and clinical development
activities, regulatory oversight, a Company’s ability to conduct its
collateral apparatus issues, competition, and a other factors discussed in
fact in a Company’s periodic filings with a Securities and
Exchange Commission. The Company undertakes no requirement to refurbish any
forward-looking statement.
SOURCE: SANUWAVE Health, Inc.
SANUWAVE Health, Inc.
Barry Jenkins, 678-578-0103
CFO
or
Bernie Laurel, 678-578-0103
VP of Sales and Marketing
investorrelations@sanuwave.com
or
Lippert/Heilshorn Associates
Investors:
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Media:
Mackenzie Mills, 212-838-3777
mmills@lhai.com
Copyright Business Wire 2012
/quotes/zigman/576958

Add SNWV to portfolio
SNWV


